SEC Form 4 · accession 0001639637-16-000002
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L. Smith
Officer — Global Head of R&D and CMO
Period of report
Apr 13, 2016
Accepted (ET)
Apr 15, 2016 · 4:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Apr 13, 2016 | F | 103 | $147.34 | D | 13,040 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.